KCM
OVID icon

Kennedy Capital Management’s Ovid Therapeutics OVID Stock Holding History

Kennedy Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,106,638
Closed -$1.44M – 578
2025
Q3 		$1.44M Sell
1,106,638
-395,691
-26% -$343K 0.03% 476
2025
Q2 		$496K Sell
1,502,329
-230,536
-13% -$69.5K 0.01% 546
2025
Q1 		$540K Buy
1,732,865
+187,478
+12% +$115K 0.01% 578
2024
Q4 		$1.44M Buy
1,545,387
+17,402
+1% +$19.5K 0.03% 558
2024
Q3 		$1.8M Buy
1,527,985
+39,414
+3% +$41.2K 0.04% 530
2024
Q2 		$1.15M Buy
+1,488,571
New +$4.14M 0.02% 578

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Kennedy Capital Management's OVID Position: Q4 2025 in Review

Kennedy Capital Management sold out of Ovid Therapeutics (OVID) in Q4 2025, closing a stake of 1,106,638 shares — an estimated $1.44M sold.

Kennedy Capital Management first reported a position in OVID in Q2 2024 and held it in 6 quarters. The position peaked at $1.8M in Q3 2024. 84 funds tracked by Wall St. Rank hold OVID as of Q4 2025.

  • Kennedy Capital Management reported no remaining Ovid Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 1,106,638 Ovid Therapeutics shares in Q4 2025, an estimated $1.44M.
  • Kennedy Capital Management first reported a position in Ovid Therapeutics in Q2 2024 and held it in 6 quarters.
  • Kennedy Capital Management's Ovid Therapeutics position peaked at $1.8M in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2025.

Based on Kennedy Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.